Matinas BioPharma Initiates Dosing In Phase 1 Study Of Potential First Oral Aminoglycoside Antibiotic Drug MAT2501
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal